What is the efficacy of chimeric antigen receptor (CAR) T-cell therapy for solid tumors?

Updated: Dec 17, 2020
  • Author: Sameh Gaballa, MD, MS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Preclinical data on CAR T therapy in solid tumors are exciting but clinical data is still in its infancy, involving mostly phase I studies. Several challenges stand in the way of using CAR T cells in solid tumors, such as identification of a truly tumor-specific antigen that is not expressed on normal tissues, as well as a hostile tumor micro-environment. Serious off-tumor toxicities have been observed in solid tumor CAR T trials, including liver, cardiac, central nervous system, and lung toxicity. [30, 31, 32] There are currently many ongoing clinical trials using CAR T cells in solid tumors, including common malignancies such as colorectal, prostate, breast, and pancreatic cancer.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!